GSK secures Japan Orphan Drug status for lung cancer ADC

TheraCryf advances lead addiction programme to final preclinical stage

Dizal meets primary endpoint in Phase 3 study of ZEGFROVY (sunvozertinib) monotherapy

Innovent Biologics reports first participant dosed in tigulixostat Phase 3 study

Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn

Humacyte prices USD20m registered direct offering

Curia expands Glasgow manufacturing capacity and enhances CLD platform

Congruence Therapeutics secures USD39.5m financing

Pfizer reports Phase 3 TALAPRO-3 results showing improved outcomes in metastatic prostate cancer

Specific Biologics and Western University win grant to develop ML platform to accelerate development of Dualase-based therapeutics 

Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform

IsomAb names new CEO

Mirecule expands collaboration with Sanofi to advance FSHD therapy

Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease

Alebund Pharmaceuticals signs licensing and equity agreements with R1 Therapeutics